Safety of capecitabine plus bevacizumab in heavily treated patients with metastatic colorectal cancer (MCRC)

被引：0
|
作者：
Adamo, Vincenzo [1 ]
Festa, Vincenzo [1 ]
Restuccia, Eleonora [1 ]
Chiofalo, Giuseppe [1 ]
Maisano, Carmelo [1 ]
Picciotto, Maria [1 ]
Alafaci, Elisabetta [1 ]
Tortora, Giampaolo [2 ]
机构：
[1] AO Univ Polyclin G Martino, Dept Human Pathol, Med Oncol & Integrated Therapies Unit, Messina, Italy
[2] Univ Naples Federico 2, Dept Mol & Clin Endocrinol & Oncol, Naples, Italy
来源：
ANNALS OF ONCOLOGY | 2007年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：16 / 17
页数：2
相关论文
共 50 条
  • [31] Capecitabine plus bevacizumab (Cape-Bev) as a maintenance treatment after induction treatment with FOLFIRI plus bevacizumab (FOLFIRI-Bev) in metastatic colorectal cancer (mCRC).
    Tatli, Ali Murat
    Coskun, Hasan Senol
    Uysal, Mukremin
    Goksu, Sema Sezgin
    Arslan, Deniz
    Gunduz, Seyda
    Ozdogan, Mustafa
    Bozcuk, Hakan Sat
    Savas, Burhan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [32] Evaluation of quality of life (QoL) in patients (pts) with metastatic colorectal cancer (MCRC) treated with capecitabine (X)
    Segalla, J
    van Eyll, B
    Federico, M
    Perdicaris, M
    Cabral, S
    Skare, N
    Saltz, E
    Moura, G
    Filho, U
    Franke, F
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 751S - 751S
  • [33] Pharmacogenetic study in patients (pts) with metastatic breast (MBC) and colorectal cancer (MCRC) treated with capecitabine (C)
    Alba, E.
    Ribelles, N.
    Sanchez, A.
    Lopez Siles, J.
    Sanchez, M. J.
    Gonzalez, E.
    Carabantes, F.
    Sanchez Rovira, P.
    Marquez, A.
    Sevilla, I.
    EJC SUPPLEMENTS, 2005, 3 (02): : 66 - 66
  • [34] Safety and pharmacokinetic (PK) study of perifosine plus capecitabine (P-CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC)
    Greco, F. A.
    Infante, J. R.
    Burris, H. A.
    Jones, S. F.
    Kolesar, J.
    Gardner, L. R.
    Sportelli, P.
    Bendell, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [35] Phase II study of capecitabine, oxaliplatin and erlotinib in previously treated patients with metastatic colorectal cancer (MCRC).
    Meyerhardt, JA
    Xhu, A
    Enzinger, PC
    Ryan, DP
    Clark, JW
    Kulke, MH
    Michelini, A
    Vincitore, M
    Thomas, A
    Fuchs, CS
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 265S - 265S
  • [36] Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
    Miller, KD
    Chap, LI
    Holmes, FA
    Cobleigh, MA
    Marcom, PK
    Fehrenbacher, L
    Dickler, M
    Overmoyer, BA
    Reimann, JD
    Sing, AP
    Langmuir, V
    Rugo, HS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) : 792 - 799
  • [37] Use of FOLFOXIRI plus bevacizumab in metastatic colorectal cancer (mCRC): An agestratified analysis.
    Vassilev, Zdravko
    Fan, Xiaozhou
    Ostojic, Helene
    Xu, Julie
    Barzi, Afsaneh
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 64 - 64
  • [38] A phase Ib study of the safety and efficacy of atezolizumab (atezo) plus bevacizumab (bev) plus cobimetinib (cobi) in patients (pts) with metastatic colorectal cancer (mCRC)
    Bendell, J.
    Lieu, C.
    Raghav, K. P. S.
    Argiles, G.
    Cubillo, A.
    Qu, X.
    Yan, Y.
    Merchant, M.
    Zeuner, H.
    Gallo, J. D.
    Segal, N. H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [39] Capecitabine plus irinotecan (CAPIRI) as first-line treatment for patients (Pts) with metastatic colorectal cancer (MCRC)
    Laudani, A.
    Savio, G.
    Leonardi, V.
    Palmisano, V.
    Tartaglia, L.
    Manuguerra, G.
    Pepe, A.
    Alu, M.
    Usset, A.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2007, 18 : 6 - 6
  • [40] Capecitabine plus irinotecan (CAPIRI) as first-line treatment for patients (PTS) with metastatic colorectal cancer (MCRC)
    Laudani, Agata
    Savio, Giuseppina
    Leonardi, Vita
    Palmisano, Valentina
    Rondello, Giacomo
    Alu, Massimiliano
    Pepe, Alessio
    Calabria, Caterina
    Usset, Antonella
    Agostara, Biagio
    ANNALS OF ONCOLOGY, 2006, 17 : 119 - 119
12345